Drug Combination Details
| General Information of the Combination (ID: C28471) | |||||
|---|---|---|---|---|---|
| Name | Thymoquinone NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute lymphoblastic leukemia
[ICD-11: 2B33]
|
Investigative | [1] | ||
|
Anaplastic large cell lymphoma
[ICD-11: 2A90]
|
Investigative | [2] | |||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Thymoquinone improved the anti-cancer properties of doxorubicin in a cell line-specific manner. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | COL11A2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | |||
| Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
| L-02 | CVCL_6926 | Ovarian cancer | Homo sapiens | |||
| Experimental
Result(s) |
TQ synergistically improves the anti-cancer activity of DOX, and loss of p53 sensitizes HCC cells to TQ-induced apoptosis. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MKI67 | Molecule Info | ||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HuT 102 | CVCL_3526 | Mycosis fungoides and Sezary syndrome | Homo sapiens | ||
| Jurkat | CVCL_0065 | T acute lymphoblastic leukemia | Homo sapiens | |||
| In-vivo Model | 7.5 * 106 HuT-102 tumor cells in 100 ul Media:Matrigel (1:1 ratio) were inoculated subcutaneously in the right flank of NOD/SCID mice (6-8 weeks, ~20 g). | |||||
| Experimental
Result(s) |
Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms. | |||||
